Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.42 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.41 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.41 |
| ▸ | HPGDS | O60760 | 1/20 | 0.40 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.40 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.40 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.40 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.39 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.39 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.39 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.38 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.38 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.38 |
| ▸ | TLR2 | O60603 | 1/20 | 0.38 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.38 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.38 |
| ▸ | ECE1 | P42892 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14763091 | 1.00 | GSR (0.42) | GSRDPP8DPP9DPP7HPGDS | |
| SCHEMBL30312562 | 0.92 | FOLH1 (0.43) | GSRDPP8DPP9DPP7HPGDS | |
| SCHEMBL29510852 | 0.89 | FURIN (0.42) | DPP8DPP9DPP7NOD1UTS2R | |
| SCHEMBL11765786 | 0.89 | FOLH1 (0.53) | GSRDPP8DPP9DPP7NOD1 | |
| SCHEMBL14959945 | 0.89 | FOLH1 (0.53) | GSRDPP8DPP9DPP7NOD1 | |
| SCHEMBL22199726 | 0.89 | FOLH1 (0.45) | GSRDPP8DPP9DPP7HPGDS | |
| SCHEMBL5997604 | 0.89 | FOLH1 (0.53) | GSRDPP8DPP9DPP7NOD1 | |
| SCHEMBL10700763 | 0.89 | FOLH1 (0.53) | GSRDPP8DPP9DPP7NOD1 | |
| SCHEMBL29376049 | 0.89 | FOLH1 (0.53) | GSRDPP8DPP9DPP7NOD1 | |
| SCHEMBL7570529 | 0.88 | DPP8 (0.51) | GSRDPP8DPP9DPP7HPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3019184-A1 | ANALOGS OF PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE (PACAP) AND METHODS FOR THEIR USE | The Administrators of the Tulane Educational Fund (US) | 2016-05-18 | — | — | EP | claimed |
| US-20160122406-A1 | ANALOGS OF PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE (PACAP) AND METHODS FOR THEIR USE | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND | 2016-05-05 | — | — | US | claimed |
| US-20150104388-A1 | ANALOGS OF PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE (PACAP) AND METHODS FOR THEIR USE | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND | 2015-04-16 | — | — | US | claimed |
| WO-2014197909-A1 | ANALOGS OF PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE (PACAP) AND METHODS FOR THEIR USE | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2014-12-11 | — | — | WO | claimed |
| US-20130065816-A1 | ANALOGS OF PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE (PACAP) AND METHODS FOR THEIR USE | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2013-03-14 | — | — | US | claimed |
| EP-2496245-A2 | ANALOGS OF PITUTARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE (PACAP) AND METHODS FOR THEIR USE | The Administrators Of The Tulane (US) | 2012-09-12 | — | — | EP | claimed |
| WO-2011054001-A2 | ANALOGS OF PITUTARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE (PACAP) AND METHODS FOR THEIR USE | THE ADMINISTRATORS OF THE TULANE (US) | 2011-05-05 | — | — | WO | claimed |
| US-20240116984-A1 | MODIFIED PEPTIDES FOR THE INHIBITION OF ABNORMAL TAU ACCUMULATION | NATIONAL SCIENCE FOUNDATION | 2024-04-11 | — | — | US | disclosed |
| EP-3019184-A1 | ANALOGS OF PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE (PACAP) AND METHODS FOR THEIR USE | The Administrators of the Tulane Educational Fund (US) | 2016-05-18 | — | — | EP | disclosed |
| US-20160122406-A1 | ANALOGS OF PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE (PACAP) AND METHODS FOR THEIR USE | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND | 2016-05-05 | — | — | US | disclosed |
| WO-2014197909-A1 | ANALOGS OF PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE (PACAP) AND METHODS FOR THEIR USE | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2014-12-11 | — | — | WO | disclosed |
| US-6399316-B1 | DRUG SCREENING OF PITUITARY ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE RECEPTOR PROTEIN BY DETECTING CHANGE IN RECEPTOR ACTIVITY IN PRESENCE OR ABSENCE OF TEST COMPOUND | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116984-A1 | MODIFIED PEPTIDES FOR THE INHIBITION OF ABNORMAL TAU ACCUMULATION | PRNP, MAPT, APP | GSR 2814/4885DPP8 2525/4885DPP9 1922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.